Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunome Inc (NQ: IMNM ) 15.76 -0.75 (-4.54%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 838,328 Open 16.50 Bid (Size) 15.70 (1) Ask (Size) 15.85 (9) Prev. Close 16.51 Today's Range 14.76 - 16.81 52wk Range 6.130 - 30.96 Shares Outstanding 59,968,868 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities July 25, 2024 From Immunome, Inc. Via Business Wire Immunome Appoints Phil Tsai as Chief Technical Officer June 27, 2024 From Immunome, Inc. Via Business Wire Performance YTD +43.14% +43.14% 1 Month +29.18% +29.18% 3 Month +14.04% +14.04% 6 Month -18.34% -18.34% 1 Year +120.11% +120.11% More News Read More Evaluating Immunome: Insights From 4 Financial Analysts May 31, 2024 Via Benzinga Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying May 22, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session May 21, 2024 Via Benzinga Immunome Announces Completion of Purchase of Assets from Atreca May 20, 2024 From Immunome, Inc. Via Business Wire Immunome Announces Promotion of Max Rosett to Chief Financial Officer May 17, 2024 From Immunome, Inc. Via Business Wire IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 May 14, 2024 Via InvestorPlace Immunome Reports First Quarter 2024 Financial Results and Provides Business Update May 14, 2024 From Immunome, Inc. Via Business Wire Immunome to Present at 2024 Bank of America Healthcare Conference May 08, 2024 From Immunome, Inc. Via Business Wire Immunome Appoints Kinney Horn as Chief Business Officer May 02, 2024 From Immunome, Inc. Via Business Wire Immunome Appoints Sandra M. Swain to Board of Directors April 25, 2024 From Immunome Via Business Wire Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting April 05, 2024 From Immunome, Inc. Via Business Wire IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 March 28, 2024 Via InvestorPlace Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets March 28, 2024 From Immunome, Inc. Via Business Wire Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday? March 28, 2024 Via Benzinga Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala March 26, 2024 From Immunome, Inc. Via Business Wire Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome March 26, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday March 22, 2024 Via Benzinga Topics Stocks Exposures US Equities Immunome to Participate in the Leerink Partners Global Biopharma Conference March 07, 2024 From Immunome, Inc. Via Business Wire Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference March 01, 2024 From Immunome, Inc. Via Business Wire Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue? February 28, 2024 Via Benzinga How I Swing Trade Via Strength With Recent Examples February 25, 2024 Via Talk Markets Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Immunome, Inc. Via Business Wire Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
